Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005227235
Thu, 30.03.2023
Biotest AG
PRESS RELEASE
Biotest achieves important milestone in phase III trial in acquired fibrinogen deficiency
Successful interim analysis performed with 80% of evaluable patients
Originally planned number of patients confirmed
Completion of trial expected in 2023
AdFIrst trial will be the basis for approval of Biotest’s human fibrinogen [ … ]
Thu, 23.03.2023
Biotest AG
PRESS RELEASE
Biotest core business profitable at Euro 60.7 million
First product from Biotest Next Level facility: approval and market launch of Yimmugo in November 2022
34 own plasma collection centres in Europe
Biotest invites to the Annual General Meeting on 9 May 2023
Dreieich, 23 March 2023. In the financial year 2022, the B [ … ]
Thu, 23.03.2023
Biotest AG
PRESS RELEASE
Biotest core business profitable at Euro 60.7 million
First product from Biotest Next Level facility: approval and market launch of Yimmugo in November 2022
34 own plasma collection centres in Europe
Biotest invites to the Annual General Meeting on 9 May 2023
Dreieich, 23 March 2023. In the financial year 2022, the B [ … ]
Tue, 14.03.2023
Biotest AG
PRESS RELEASE
Biotest donates human albumin for earthquake victims in Turkey
Almost 2,000 severely affected victims can be supplied with human albumin
Close interaction with Turkish Red Crescent (Kizilay) and the Turkish-German Health Foundation e.V. (Türk Alman Saglik Vakfi)
Dreieich, 14 March 2023. As a manufacturer of life-saving [ … ]
Tue, 14.03.2023
Biotest AG
PRESS RELEASE
Biotest donates human albumin for earthquake victims in Turkey
Almost 2,000 severely affected victims can be supplied with human albumin
Close interaction with Turkish Red Crescent (Kizilay) and the Turkish-German Health Foundation e.V. (Türk Alman Saglik Vakfi)
Dreieich, 14 March 2023. As a manufacturer of life-saving [ … ]
Fri, 10.02.2023
Biotest AG
PRESS RELEASE
Biotest Supervisory Board appoints new Management Board member
Ainhoa Mendizabal will assume the position of Chief Financial Officer (CFO) on the Management Board on 15 February
Dreieich, 10 February 2023. The Supervisory Board of Biotest AG has appointed Ms Ainhoa Mendizabal (50) to the company's Management Board as Chief Financia [ … ]
Fri, 10.02.2023
Biotest AG
PRESS RELEASE
Biotest Supervisory Board appoints new Management Board member
Ainhoa Mendizabal will assume the position of Chief Financial Officer (CFO) on the Management Board on 15 February
Dreieich, 10 February 2023. The Supervisory Board of Biotest AG has appointed Ms Ainhoa Mendizabal (50) to the company's Management Board as Chief Financia [ … ]
Thu, 09.02.2023
Biotest AG
Ad hoc NOTICE
Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR)
Biotest significantly exceeds EBIT guidance 2022
Dreieich, 09 February 2023. According to preliminary and not yet audited figures, the Biotest Group slightly increased its revenues to € 516.1 million in the financial year 2022, compared to € 515.6 million in [ … ]
Thu, 09.02.2023
Biotest AG
Ad hoc NOTICE
Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR)
Biotest significantly exceeds EBIT guidance 2022
Dreieich, 09 February 2023. According to preliminary and not yet audited figures, the Biotest Group slightly increased its revenues to € 516.1 million in the financial year 2022, compared to € 515.6 million in [ … ]
Tue, 24.01.2023
Biotest AG
PRESS RELEASE
First patient treated with Cytotect® CP Biotest in study after heart and lung transplantation
High medical need due to severe cytomegalovirus (CMV) infections and resulting mortality after organ transplantation
Study will provide data to optimise treatment strategies with CMV hyperimmunoglobulins after heart and lung tr [ … ]